Q1 Earnings Forecast for SGMT Issued By HC Wainwright

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Sagimet Biosciences in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.52) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.52) EPS and FY2030 earnings at $0.99 EPS.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14.

A number of other brokerages have also issued reports on SGMT. Citizens Jmp boosted their target price on shares of Sagimet Biosciences from $33.00 to $35.00 and gave the company a “market outperform” rating in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Guggenheim initiated coverage on shares of Sagimet Biosciences in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Barclays assumed coverage on Sagimet Biosciences in a report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.00.

Sagimet Biosciences Stock Performance

Shares of NASDAQ SGMT opened at $5.21 on Friday. The business’s 50 day moving average price is $5.73 and its 200-day moving average price is $6.62. Sagimet Biosciences has a fifty-two week low of $1.73 and a fifty-two week high of $11.41. The company has a market cap of $169.43 million, a price-to-earnings ratio of -3.32 and a beta of 3.35.

Hedge Funds Weigh In On Sagimet Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Sagimet Biosciences by 4.3% in the third quarter. Vanguard Group Inc. now owns 1,203,231 shares of the company’s stock worth $8,254,000 after buying an additional 49,375 shares in the last quarter. Affinity Asset Advisors LLC boosted its position in Sagimet Biosciences by 228.1% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock valued at $6,798,000 after acquiring an additional 798,245 shares in the last quarter. Marshall Wace LLP bought a new stake in Sagimet Biosciences during the 4th quarter valued at $4,620,000. Millennium Management LLC increased its holdings in shares of Sagimet Biosciences by 6,484.7% in the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock valued at $5,326,000 after acquiring an additional 788,537 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its position in shares of Sagimet Biosciences by 462.4% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after acquiring an additional 430,644 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO David Happel sold 12,101 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the sale, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 14.70% of the company’s stock.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.